Frontiers in endocrinology · 2026
Prevalence and associated factors of gestational diabetes mellitus among women with polycystic ovary syndrome: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yuan Youchang, Hu Liuxin, Li Yanjing, Hou Xinju
Аннотация
OBJECTIVE: Polycystic ovary syndrome (PCOS), the most common endocrine disorder in reproductive-aged women, often leads to gestational diabetes mellitus (GDM). This study aimed to systematically evaluate GDM prevalence and its associated factors in PCOS.
METHODS: We searched PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang, Sinomed, and VIP from inception to December 31, 2025. Studies reporting GDM prevalence or associated factors in PCOS were included. A random-effects model pooled prevalence with odds ratios. Egger's test assessed publication bias, and subgroup analysis with meta-regression explored heterogeneity. A logit transformation was applied for pooling.
RESULTS: Twenty-two studies with 5,507 PCOS patients were included. The pooled GDM prevalence was 24% (95% CI: 20%-28%; prediction interval: 10%-46%), with substantial heterogeneity (I² = 89.9%). The primary prevalence estimate, based on cohort studies (n=13), was 21.7% (95% CI: 17.7%-25.8%), while the overall estimate including case-control studies was 24% (95% CI: 20%-28%). By diagnostic criteria, GDM prevalence was 26.0% for one-step vs. 18.7% for two-step. Potentially associated factors included pre-pregnancy BMI (OR = 1.39), gestational weight gain (OR = 1.58), HOMA-IR (OR = 3.41), and family history of diabetes (OR = 2.88).
CONCLUSION: Although the pooled GDM prevalence in PCOS was 24%, substantial heterogeneity and a wide prediction interval (10%-46%) suggest the true prevalence varies considerably across settings. Associated factors included HOMA-IR, family history, pre-pregnancy overweight, and excessive gestational weight gain. PCOS patients should be considered a high-risk group, and early monitoring of glucose metabolism and weight management may be beneficial, though these recommendations derive from observed rather than interventional evidence.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42026128476, identifier: CRD420261284765.
METHODS: We searched PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang, Sinomed, and VIP from inception to December 31, 2025. Studies reporting GDM prevalence or associated factors in PCOS were included. A random-effects model pooled prevalence with odds ratios. Egger's test assessed publication bias, and subgroup analysis with meta-regression explored heterogeneity. A logit transformation was applied for pooling.
RESULTS: Twenty-two studies with 5,507 PCOS patients were included. The pooled GDM prevalence was 24% (95% CI: 20%-28%; prediction interval: 10%-46%), with substantial heterogeneity (I² = 89.9%). The primary prevalence estimate, based on cohort studies (n=13), was 21.7% (95% CI: 17.7%-25.8%), while the overall estimate including case-control studies was 24% (95% CI: 20%-28%). By diagnostic criteria, GDM prevalence was 26.0% for one-step vs. 18.7% for two-step. Potentially associated factors included pre-pregnancy BMI (OR = 1.39), gestational weight gain (OR = 1.58), HOMA-IR (OR = 3.41), and family history of diabetes (OR = 2.88).
CONCLUSION: Although the pooled GDM prevalence in PCOS was 24%, substantial heterogeneity and a wide prediction interval (10%-46%) suggest the true prevalence varies considerably across settings. Associated factors included HOMA-IR, family history, pre-pregnancy overweight, and excessive gestational weight gain. PCOS patients should be considered a high-risk group, and early monitoring of glucose metabolism and weight management may be beneficial, though these recommendations derive from observed rather than interventional evidence.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42026128476, identifier: CRD420261284765.